Arthritis drug effective in most severely ill COVID-19 patients

Organisation: Position: Deadline Date: Location:

The rheumatoid arthritis drug tocilizumab significantly improves outcomes in ICU patients with COVID-19, show early results from the Remap-Cap international platform trial. Previous studies produced mixed results.

The findings have not been peer-reviewed or published, but if confirmed by more trial data, the drug will be on track to become only the second effective therapy for the sickest Covid patients, following positive results for the steroid dexamethasone earlier this year.

The BMJ reports that the Remap-Cap (A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia) trial has enrolled over 2000 patients in 15 countries who are randomly assigned to multiple treatment combinations. Remap-Cap is led by Imperial College London and the Intensive Care National Audit & Research Centre (ICNARC) in the UK and Utrecht University in Europe.

It is also evaluating therapeutic anticoagulation, convalescent plasma, vitamin C, and macrolides. The study is supported in the UK by the National Institute for Health Research.

The researchers reported that critically ill patients receiving tocilizumab were more likely to improve than patients who received no immune modulator (odds ratio 1.87). “These are very exciting and encouraging results,” said the chief investigator, Anthony Gordon, consultant in intensive care medicine at Imperial College Healthcare NHS Trust, at a briefing on 19 November.

“This is an absolutely amazing result,” said Dr Lennie Derde, Consultant in Intensive Care Medicine at the University Medical Center in Utrecht and the Immune Modulation Domain Specific Working Group Chair. “To have a second effective therapy for critically ill patients within months of the start of the pandemic is unprecedented. Specific targeting of the immune response is theoretically attractive, and now we have shown it works.”

However, Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine, said, “The size of the beneficial effect reported in this trial does not appear that high, and it combines survival with need for intense support. Therefore, I think these results need to be treated with caution at this early stage.”

“Perhaps combining the data from all the reported trials would suggest there is benefit of taking tocilizumab when severely ill with Covid-19 but it may not be large,” he said. Some critically ill patients die from overwhelming inflammation that is triggered by severe pneumonia caused by the virus, so dampening down the inflammation may help.

“It is possible that different drugs work best at different times during illness with Covid. It seems remdesivir may well work early in the disease process, and not at later stages, while dexamethasone works well at later periods, and not in earlier stages of the disease,” he added. Dexamethasone, which costs about £5 per dose, was found in trials to cut the risk of death by a third for patients on ventilators. It is now part of standard care for Covid patients in hospital.

Gordon said Remap-Cap’s data was a bigger result than the 1.43 odds ratio seen with the steroid dexamethasone reported earlier by the trial.

However, the results are based on a combined outcome measure of survival and the length of time patients need organ support, such as a breathing machine, and the relative contribution of each has not yet been analysed. The results were made available by press release and have not yet been peer reviewed.

Previous studies on the immune modulator tocilizumab have produced mixed results. A recent trial conducted among inpatients and reported in the New England Journal of Medicine did not find a survival benefit in those taking tocilizumab; however, they were less severely ill than those in the Remap-Cap trial.2

Best combination

The latest analysis was carried out by a statistical analysis committee separate from the trial investigators and reviewed by an independent data and safety monitoring board. The board advised the trial to stop recruiting patients into the no immune modulator arm on the basis of the findings.

The analysis included data from the first 303 patients randomly assigned to receive immune modulation treatments (tocilizumab, sarilumab, anakinra, or interferon) or no immune modulator. The relative benefits of tocilizumab as compared with the other immune modulator drugs have not yet been reported.

Patients were given the immune modulation treatment on the first day of becoming seriously unwell and moving into intensive care. Some of the patients will also have previously received the steroid dexamethasone, but those recruited early in the trial, before it became standard practice, will not.

Gordon said, “It is unlikely that any single drug will work on its own. This is why we need to analyse the best combination of treatments.” He added that the team were working hard to analyse the results on 800 patients and hoped to publish the full results in the next few weeks.

Tocilizumab is given by intravenous infusion and works by blocking the cytokine interleukin 6. “Seriously ill patients have a lot of lung inflammation, and the drug works through its anti-cytokine effect,” Gordon explained.

The drug costs £500-£1000 (€558-€1117; $661-$1323) and is much more expensive than dexamethasone but cheaper than a longer stay in intensive care, he added.

Mixed results reported

The latest analysis also showed that the antiviral drug combination lopinavir-ritonavir was ineffective and provided no additional benefit to patients critically ill with covid-19 when compared with those who did not receive the drug (odds ratio 0.67). The Recovery trial also found that lopinavir-ritonavir did not improve survival of patients with covid-19 in hospital, although this was among less seriously ill patients.3

Peter Horby, professor of emerging infectious diseases and global health in the Nuffield Department of Medicine at the University of Oxford, commented, “The results so far on tocilizumab have been mixed, with four randomised controlled trials having reported results, of which two were negative and two were positive. None have reported a mortality benefit at day 28 or 30. The results from Remap-Cap add to this evidence base, and I eagerly look forward to seeing the full results.”

Imperial College London said in a media release that due to the clinical implications for patients, the researchers have released the findings before they have been peer-reviewed, but are working to analyse and publish the full results as soon as possible.

“The latest findings on tocilizumab and lopinavir/ritonavir add to REMAP-CAP findings from earlier this year, which found that hydrocortisone steroid treatment improved recovery among critically ill COVID-19 patients.”

 

The BMJ full report

 

Remap-Cap website


Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.